Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.

doi:10.1182/bloodadvances.2021005682

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.

Blood advances - 14 Dec 2021

Pighi Chiara, Cheong Taek-Chin, Compagno Mara, Patrucco Enrico, Arigoni Maddalena, Olivero Martina, Wang Qi, López Cristina, Bernhart Stephan H, Grande Bruno M, Poggio Teresa, Langellotto Fernanda, Bonello Lisa, Dall'Olio Riccardo, Martínez-Martín Sandra, Molinaro Luca, Francia di Celle Paola, Whitfield Jonathan R, Soucek Laura, Voena Claudia, Calogero Raffaele A, Morin Ryan D, Staudt Louis M, Siebert Reiner, Zamò Alberto, Chiarle Roberto

Abstract excerpt

The expression of BCL6 in B-cell lymphoma can be deregulated by chromosomal translocations, somatic mutations in the promoter regulatory regions, or reduced proteasome-mediated degradation. FBXO11 was recently identified as a ubiquitin ligase that is involved in the degradation of BCL6, and it is frequently inactivated in lymphoma or other tumors. Here, we show that FBXO11 mutations are found in 23% of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Burkitt Lymphoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to F-Box Proteins

Share to Genes, myc

Share to Lymphoma, B-Cell

Share to Mice

Share to Mutation

Share to Protein-Arginine N-Methyltransferases

Share to Proto-Oncogene Proteins c-bcl-6

Source

Open in PubMed Open full text

Identifiers

PMID: 34625792
DOI: 10.1182/bloodadvances.2021005682
PMCID: PMC9153037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.PMID 34625792Read ↗

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.Semantic proximity Read ↗

FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative diseaseSemantic proximity Read ↗

MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.Semantic proximity Read ↗

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaSemantic proximity Read ↗

Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitinationSemantic proximity Read ↗

Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cellsSemantic proximity Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphomaSemantic proximity Read ↗

Roles of BCL6 in normal and transformed germinal center B cellsSemantic proximity Read ↗

The FBXL family of F-box proteins: variations on a themeSemantic proximity Read ↗

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaSemantic proximity Read ↗

BCL11A: a potential diagnostic biomarker and therapeutic target in human diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.